US 12,319,682 B2
Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists
Marcin Kolaczkowski, Wieliczka (PL); Adam Bucki, Przebieczany (PL); Joanna Sniecikowska, Wieliczka (PL); and Monika Marcinkowska, Cracow (PL)
Assigned to ADAMED PHARMA S.A., Czosnow (PL)
Filed by Adamed Pharma S.A, Czosnow (PL)
Filed on Apr. 16, 2024, as Appl. No. 18/637,083.
Application 18/637,083 is a continuation of application No. 17/326,159, filed on May 20, 2021, granted, now 11,981,668.
Application 17/326,159 is a continuation of application No. 16/970,871, granted, now 11,034,688, issued on Jun. 15, 2021, previously published as PCT/EP2019/054171, filed on Feb. 20, 2019.
Claims priority of application No. 18461519 (EP), filed on Feb. 21, 2018.
Prior Publication US 2024/0287056 A1, Aug. 29, 2024
Int. Cl. C07D 417/14 (2006.01); A61P 25/28 (2006.01); C07D 403/10 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01)
CPC C07D 417/14 (2013.01) [A61P 25/28 (2018.01); C07D 403/10 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01)] 20 Claims
 
1. A pharmaceutical composition comprising a compound having the structure:

OG Complex Work Unit Chemistry
wherein:
G is CH or N;
R1 is H, C1-C4-alkyl, HO-C1-C4-alkyl or C1-C4-alkyl-O—C1-C4-alkyl; and
R2 is selected from group consisting of:
(a) phenyl group unsubstituted or substituted with at least one substituent, or
(b) 5-or 6-membered heteroaryl group unsubstituted or substituted with at least one substituent,
wherein the substituent is selected from a group consisting of F, Cl, Br, C1-C4-alkyl-, and C1-C4-alkyl -O—;
or a pharmaceutically acceptable salt thereof, and scopolamine.